184 results about "Human immuno deficiency virus" patented technology

To provide methods for treating diseases.SOLUTION: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I), including stereoisomers and pharmaceutically acceptable salts thereof, where R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.SELECTED DRAWING: None

The present disclosure relates generally to compounds, of Formula (I). Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates generally to compounds, of Formula I: Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates to dosing regimens of an HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The present disclosure relates generally to compounds, of Formula (I). Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates generally to solid forms of the compound of Formula I:Also disclosed are pharmaceutical compositions comprising said solid forms and methods of making said solid forms. The solid forms of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Provided herein are methods and compositions for inducing in a subject a broad neutralizing antibody response to human immunodeficiency virus (HIV) infection.

The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates to pharmaceutical compositions comprising an HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The present disclosure relates generally to compounds, of Formula I.Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The invention relates to the technical field of biomedicine, in particular to an anti-human immunodeficiency virus type 1 p24 and type 2 p26 antibody and application thereof. The invention provides an antibody or an antigen-binding fragment thereof capable of specifically binding to a p24 protein of human immunodeficiency virus type 1 and a p26 protein of human immunodeficiency virus type 2, and also provides a combination of antibody pairs, a kit and related applications. When the antibody pair is used for immunodetection, antigens of HIV-1 type p24 and HIV-2 type p26 can be detected at the same time, and the antibody pair has the advantage of lower concentration detection limit.

The compoundand pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.

The present invention relates to compositions comprising an RNA molecule and pharmaceutical formulations comprising such compositions wherein the RNA molecule comprises an expression cassette encoding an immunogenic peptide comprising at least two fragments wherein each fragment comprises at least one epitope wherein the epitope is derived from an amino acid sequence encoded by human immunodeficiency virus (HIV). In addition, the present invention relates to a method of preventing or treating HIV.

The present disclosure relates to monoclonal human antibodies or binding fragments thereof which are directed against the CD4 binding site of the human immunodeficiency virus HIV-1, a pharmaceutical composition comprising such monoclonal human antibodies or binding fragments thereof, a kit comprising such antibodies or binding fragments thereof, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by the human immunodeficiency virus HIV-1.

Described herein is a singleplex RT-LAMP-based tests using modified primer sets. Contrived whole blood samples containing HIV-1 or HCV virions were diluted in equal parts water and loaded directly into optimized RT-LAMP master mixes. To mitigate cold-chain storage dependence, RT-LAMP reactions were performed using a lyophilized master mix. The reactions were heated for, for example 30 minutes using a hand-held, battery-powered heating device for simultaneous virion lysis and amplification.

This invention provides a wide range of neutralizing antibodies targeting the epitopes of human immunodeficiency virus (HVM) or HIV. Furthermore, it provides compositions containing antibodies for use in prevention, and methods for the diagnosis and treatment of HIV infection. [Solution] An isolated anti-HIV antibody or its antigen-binding fragment is provided, comprising a heavy chain variable region containing a specific sequence and a light chain variable region containing a specific sequence. The antibody is a recombinant antibody or a human antibody.

This invention discloses an anti-HIV antibody or a functional fragment thereof and its applications. The anti-HIV antibody or functional fragment disclosed in this invention includes a heavy chain complementarity-determining region and a light chain complementarity-determining region. This antibody or functional fragment has good specificity and sensitivity for HIV and can be used to detect human immunodeficiency virus (HIV) and for the diagnosis or auxiliary diagnosis of related diseases using HIV as a biomarker.

The invention relates to a human immunodeficiency virus detection device and a preparation method thereof, and belongs to the technical field of biomedical detection. The sample pad, the combination pad, the reaction tank pad, the cellulose membrane and the water absorption pad are sequentially overlapped and pasted on the bottom plate according to the chromatography direction to form the detection device, the reaction tank pad is made of one or more of glass fibers, polyester fibers and cellulose materials, and the reaction tank pad is obtained by soaking the reaction tank pad in a reaction tank pad treatment solution and then drying the reaction tank pad; the reaction tank pad treating fluid comprises 0.01 to 0.2 weight percent of high-molecular polymer and 0.1 to 5 weight percent of saccharide. The detection device provided by the invention has the advantages of high sensitivity and short detection time, particularly, the detection sensitivity of the antigen is higher than the national standard 2.5 IU / mL and the sensitivity of other products in the prior art and can reach 1IU / mL, and the detection device is suitable for clinical and household rapid detection requirements.

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

Engineered TCR molecules specific to retroviral peptide / HLA complexes guide direct killing and / or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (Vα) domain, a TCR variable beta domain (Vβ) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.

To provide a pharmaceutical composition useful for treating HIV infection. [Solution] A pharmaceutical composition is provided that includes, for example, the following compound or a pharmaceutically acceptable salt thereof. JPEG2026062839000055.jpg62170

The present invention relates to: a heteroaryl compound having antiviral activity, in particular, a compound of chemical formula 1, having high selectivity and physiological activity against human immunodeficiency virus (HIV), or a pharmaceutically acceptable salt, a stereoisomer, a hydrate, a solvate, a tautomer, or a prodrug thereof; and a use thereof. [Chemical formula 1]

The present disclosure relates generally to compounds of Formula I. Pharmaceutical compositions comprising the compounds and methods of making the compounds are also disclosed. The compounds of the present disclosure are useful in the treatment or prevention of human immunodeficiency virus (HIV) infection. # imgabs0 #

Antigen binding proteins of the invention bind to Human Immunodeficiency Virus (HIV) envelope protein and are useful in treating and preventing HIV infection. In particular, the antigen binding proteins bind to two different epitopes on HIV envelope surface glycoprotein 120 (gp120): the V3 loop region and the CD4 binding site.

To provide methods for treating diseases.SOLUTION: The present disclosure provides prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides, and compositions, methods and kits thereof. Such compounds can be useful for treating virus infections including human immunodeficiency virus. The compounds have the following formula (I). Provided herein are compounds functioning as antiviral agents (in some embodiments, as anti-HIV agents), pharmaceutical compositions comprising such a compound and optionally in combination with one or more (e.g., two, three or four) additional therapeutic agents, and methods for using such compounds and compositions. Embodiment of every disclosed compound includes pharmaceutically acceptable salts and stereoisomers thereof or a mixture of the stereoisomers.SELECTED DRAWING: None

The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.

The present disclosure is based on methods for determining susceptibility of a human immunodeficiency virus type-1 (HIV-1) to one or more drugs. The present disclosure is also based on methods of performing drug resistance testing in a subject with HIV-1 or suspected of or having an HIV-1 infection. The present disclosure also relates to primers useful in these methods, and kits and articles of manufacture comprising the primers.

The present disclosure provides AAV-delivered antibody compositions and kits for treating and / or preventing infectious diseases (for example, Human Immunodeficiency Virus (HIV)) and methods of use thereof.

The application provides an RT-RAP primer probe set and kit for detecting blood viruses, and belongs to the technical field of molecular biology. The primer probe set comprises a primer probe set for detecting hepatitis B virus, and / or a primer probe set for detecting hepatitis C virus, and / or a primer probe set for detecting human immunodeficiency virus. The application adopts the detection means of RT-RAA and qPCR in sequence, and can simultaneously and rapidly detect hepatitis B virus, hepatitis C virus and human immunodeficiency virus in combination with the specific primer probe set, has higher sensitivity than ordinary qPCR, greatly shortens the reaction time, and has good specificity.